Though Poly (ADP-ribose) polymerase (PARP) inhibition is at the forefront of BRCA1/2-mutant breast and ovarian cancer therapy, many new exciting targets such as POLQ, RAD52, FANCD2, FEN1, APEX2, and RNF168, appear to have therapeutic potential in pre-clinical studies [12,13,14,15,16]. This evidence concerns the gene BRCA1 and ovarian carcinoma.